Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications

AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zheji...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 18; no. 24; pp. 3167 - 3172
Main Author Zhu, Ling-Ling
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 28.06.2012
Subjects
Online AccessGet full text
ISSN1007-9327
2219-2840
2219-2840
DOI10.3748/wjg.v18.i24.3167

Cover

Abstract AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zhejiang University.The hospital has 2300 beds and 2.5 million outpatient visits annually.Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011.Concomitant use of proton-pump inhibitors(PPIs),histamine 2-receptor antagonists(H2RA) and mucoprotective drugs(MPs) were analyzed.A defined daily dose(DDD) methodology was applied to each MP.A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs(NSAIDs),corticosteroids and clopidogrel and warfarin] or intestinal protective drugs(misoprostol,rebamipide,teprenone and gefarnate).Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records.The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.RESULTS:Prescriptions for aspirin users receiving PPIs,H2RA and MPs(n = 1039) accounted for only 3.46% of total aspirin prescriptions(n = 30 015).The ratios of coadministration of aspirin/PPI,aspirin/H2RA,aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%,0.12%,0.40% and 0.12%,respectively.No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs,H2RA or MPs.The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs(2.82% vs 0.40%,P 〈 0.05) and aspirin/H2RA(2.82% vs 0.12%,P 〈 0.05).The values of DDDs of MPs in descending order were as follows:gefarnate,hydrotalcite 〉 teprenone 〉 sucralfate oral suspension 〉 L-glutamine and sodium gualenate granules 〉 rebamipide 〉 sucralfate chewable tablets.The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows:rebamipide(0.47%),teprenone(0.91%),L-glutamine and sodium gualenate granules(0.92%),gefarnate(0.31%),hydrotalcite(1.00%) and sucralfate oral suspension(0.13%).Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were:rebamipide(0.010%),PPI/rebamipide(0.027%),teprenone(0.11%),PPI/teprenone(0.037%),gefarnate(0.017%),and PPI/gefarnate(0.013%).No prescriptions were found containing coadministration of aspirin and other NSAIDs.Among the 3196 prescriptions containing aspirin/clopidogrel,3088(96.6%) prescriptions did not contain any GI protective medicines.Of the 389 prescriptions containing aspirin/corticosteroids,236(60.7%) contained no GI protective medicines.None of the prescriptions using aspirin/warfarin(n = 22) contained GI protective medicines.Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin.The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin,respectively.CONCLUSION:The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications.Actions should be taken to address this issue.
AbstractList AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zhejiang University.The hospital has 2300 beds and 2.5 million outpatient visits annually.Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011.Concomitant use of proton-pump inhibitors(PPIs),histamine 2-receptor antagonists(H2RA) and mucoprotective drugs(MPs) were analyzed.A defined daily dose(DDD) methodology was applied to each MP.A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs(NSAIDs),corticosteroids and clopidogrel and warfarin] or intestinal protective drugs(misoprostol,rebamipide,teprenone and gefarnate).Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records.The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.RESULTS:Prescriptions for aspirin users receiving PPIs,H2RA and MPs(n = 1039) accounted for only 3.46% of total aspirin prescriptions(n = 30 015).The ratios of coadministration of aspirin/PPI,aspirin/H2RA,aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%,0.12%,0.40% and 0.12%,respectively.No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs,H2RA or MPs.The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs(2.82% vs 0.40%,P 〈 0.05) and aspirin/H2RA(2.82% vs 0.12%,P 〈 0.05).The values of DDDs of MPs in descending order were as follows:gefarnate,hydrotalcite 〉 teprenone 〉 sucralfate oral suspension 〉 L-glutamine and sodium gualenate granules 〉 rebamipide 〉 sucralfate chewable tablets.The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows:rebamipide(0.47%),teprenone(0.91%),L-glutamine and sodium gualenate granules(0.92%),gefarnate(0.31%),hydrotalcite(1.00%) and sucralfate oral suspension(0.13%).Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were:rebamipide(0.010%),PPI/rebamipide(0.027%),teprenone(0.11%),PPI/teprenone(0.037%),gefarnate(0.017%),and PPI/gefarnate(0.013%).No prescriptions were found containing coadministration of aspirin and other NSAIDs.Among the 3196 prescriptions containing aspirin/clopidogrel,3088(96.6%) prescriptions did not contain any GI protective medicines.Of the 389 prescriptions containing aspirin/corticosteroids,236(60.7%) contained no GI protective medicines.None of the prescriptions using aspirin/warfarin(n = 22) contained GI protective medicines.Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin.The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin,respectively.CONCLUSION:The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications.Actions should be taken to address this issue.
To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications. A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients. Prescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively. The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.
AIM: To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications. METHODS: A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients. RESULTS: Prescriptions for aspirin users receiving PPIs, H2RA and MPs ( n = 1039) accounted for only 3.46% of total aspirin prescriptions ( n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin ( n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively. CONCLUSION: The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.
To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications.AIMTo investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications.A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.METHODSA retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.Prescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively.RESULTSPrescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively.The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.CONCLUSIONThe prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.
Author Ling-Ling Zhu Ling-Cheng Xu Yan Chen Quan Zhou Su Zeng
AuthorAffiliation Geriatric Ward, the 2nd Affiliated Hospital,School of Medicine, Zhejiang University, Hangzhou 310009,Zhejiang Province, China Department of Pharmacy, the2nd Affiliated Hospital, School of Medicine, Zhejiang Univer-sity, Hangzhou 310009, Zhejiang Province, China Department of Gastroenterology, the 2nd AffiliatedHospital. School of Medicine, Zhejiang University, Hangzhou310009, Zhejiang Province, China Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang Uni- versity, Hangzhou 310058, Zhejiang Province, China
Author_xml – sequence: 1
  givenname: Ling-Ling
  surname: Zhu
  fullname: Zhu, Ling-Ling
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22791953$$D View this record in MEDLINE/PubMed
BookMark eNp9kT1v2zAQhokiReOk3TsV6tZFLskjRWkpUAT9AgK0QzITFEXJZ8ikQko28u_DNE7QZshCDvd-4O45Iyc-eEfIe0bXoET9-bAd1ntWr5GLNbBKvSIrzllT8lrQE7JilKqyAa5OyVlKW0o5gORvyCnnqmGNhBXBPyHEwhxMdN6lVIS-mKLbOz-jHwqTJozoS_TdYl1XDCbNMaCfXcpzMxbot0u8LQ44bwobdi36rJpimJ2dce-KnevQmhmDT2_J696Myb07_ufk-vu3q4uf5eXvH78uvl6WVnA-lxVjTQ99fquWCyEALFSK21YaKaXqu7bvHJVOtcI0QlQ221oJyqgOLG0onJMvD7nT0uZ6m1eJZtRTxJ2JtzoY1P9PPG70EPYaoK4AWA74dAyI4WbJm-odJuvG0XgXlqQZ5aIBAbXM0g__dj2VPN43C6oHgY0hpeh6bXH-e49cjWPO0vcgdQapM0idQep7kNlInxkfs1-wfDxaNsEPN5nfk0dwSRsOFO4A5q-xBQ
CitedBy_id crossref_primary_10_1007_s40278_021_94529_1
crossref_primary_10_4330_wjc_v15_i8_375
crossref_primary_10_1155_2019_6532876
crossref_primary_10_1111_jphp_13227
crossref_primary_10_4103_pm_pm_333_21
crossref_primary_10_3810_pgm_2014_01_2728
crossref_primary_10_1016_j_cpcardiol_2017_01_006
crossref_primary_10_3389_fmed_2021_647494
crossref_primary_10_2174_1381612826666201102101758
crossref_primary_10_1007_s12272_018_1068_5
crossref_primary_10_1097_CRD_0000000000000174
crossref_primary_10_1016_j_amjmed_2012_10_026
crossref_primary_10_1371_journal_pone_0131558
crossref_primary_10_1016_j_ajpc_2022_100363
crossref_primary_10_1016_j_cej_2020_127176
crossref_primary_10_1007_s40261_017_0519_y
ContentType Journal Article
Copyright 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012
Copyright_xml – notice: 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v18.i24.3167
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications
EISSN 2219-2840
EndPage 3172
ExternalDocumentID PMC3386331
22791953
10_3748_wjg_v18_i24_3167
42509230
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c422t-6119f3f1196b244433c3672cb5a5557fdbfde05e7b4a9446cc42b537a7d3c0903
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 18:34:26 EDT 2025
Fri Jul 11 00:08:15 EDT 2025
Mon Jul 21 06:05:10 EDT 2025
Thu Apr 24 22:58:38 EDT 2025
Tue Jul 01 03:21:56 EDT 2025
Wed Feb 14 10:46:24 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 24
Keywords Small bowel injury
Drug utilization
Prescribing patterns
Histamine 2-receptor antagonists
Defined daily dose
Low-dose aspirin
Combined medications
Proton-pump inhibitors
Gastrointestinal injury
Mucoprotective drugs
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c422t-6119f3f1196b244433c3672cb5a5557fdbfde05e7b4a9446cc42b537a7d3c0903
Notes 14-1219/R
AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zhejiang University.The hospital has 2300 beds and 2.5 million outpatient visits annually.Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011.Concomitant use of proton-pump inhibitors(PPIs),histamine 2-receptor antagonists(H2RA) and mucoprotective drugs(MPs) were analyzed.A defined daily dose(DDD) methodology was applied to each MP.A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs(NSAIDs),corticosteroids and clopidogrel and warfarin] or intestinal protective drugs(misoprostol,rebamipide,teprenone and gefarnate).Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records.The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.RESULTS:Prescriptions for aspirin users receiving PPIs,H2RA and MPs(n = 1039) accounted for only 3.46% of total aspirin prescriptions(n = 30 015).The ratios of coadministration of aspirin/PPI,aspirin/H2RA,aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%,0.12%,0.40% and 0.12%,respectively.No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs,H2RA or MPs.The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs(2.82% vs 0.40%,P 〈 0.05) and aspirin/H2RA(2.82% vs 0.12%,P 〈 0.05).The values of DDDs of MPs in descending order were as follows:gefarnate,hydrotalcite 〉 teprenone 〉 sucralfate oral suspension 〉 L-glutamine and sodium gualenate granules 〉 rebamipide 〉 sucralfate chewable tablets.The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows:rebamipide(0.47%),teprenone(0.91%),L-glutamine and sodium gualenate granules(0.92%),gefarnate(0.31%),hydrotalcite(1.00%) and sucralfate oral suspension(0.13%).Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were:rebamipide(0.010%),PPI/rebamipide(0.027%),teprenone(0.11%),PPI/teprenone(0.037%),gefarnate(0.017%),and PPI/gefarnate(0.013%).No prescriptions were found containing coadministration of aspirin and other NSAIDs.Among the 3196 prescriptions containing aspirin/clopidogrel,3088(96.6%) prescriptions did not contain any GI protective medicines.Of the 389 prescriptions containing aspirin/corticosteroids,236(60.7%) contained no GI protective medicines.None of the prescriptions using aspirin/warfarin(n = 22) contained GI protective medicines.Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin.The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin,respectively.CONCLUSION:The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications.Actions should be taken to address this issue.
Low-dose aspirin; Gastrointestinal injury;Small bowel injury; Drug utilization; Prescribing patterns;Combined medications; Proton-pump inhibitors; Hista-mine 2-receptor antagonists; IVlucoprotective drugs; De-fined daily dose
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: Zhu LL and Zhou Q conceived and designed research; Xu LC collected data from the Hospital Information System; Zhou Q and Chen Y performed literature review and data analysis; and Zhou Q and Zeng S wrote the paper.
Correspondence to: Quan Zhou, PhD, Professor, Clinical Pharmacy Specialist, Department of Pharmacy, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China. zhouquan142602@zju.edu.cn
Telephone: +86-571-87784615 Fax: +86-571-87022776
OpenAccessLink https://www.wjgnet.com/1007-9327/full/v18/i24/3167.htm
PMID 22791953
PQID 1024934385
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3386331
proquest_miscellaneous_1024934385
pubmed_primary_22791953
crossref_citationtrail_10_3748_wjg_v18_i24_3167
crossref_primary_10_3748_wjg_v18_i24_3167
chongqing_primary_42509230
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-06-28
PublicationDateYYYYMMDD 2012-06-28
PublicationDate_xml – month: 06
  year: 2012
  text: 2012-06-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2012
Publisher Baishideng Publishing Group Co., Limited
Publisher_xml – name: Baishideng Publishing Group Co., Limited
References 21464720 - Eur J Gastroenterol Hepatol. 2011 May;23(5):396-404
18995219 - Clin Gastroenterol Hepatol. 2008 Nov;6(11):1279-82
19968611 - Scand J Gastroenterol. 2010 Mar;45(3):292-8
21072898 - World J Gastroenterol. 2010 Nov 14;16(42):5342-6
22093203 - Am Heart J. 2011 Nov;162(5):870-4
20588029 - Digestion. 2010;82(3):167-72
18477341 - Am J Gastroenterol. 2008 May;103(5):1097-103
10792114 - Aliment Pharmacol Ther. 2000 May;14(5):529-34
21130762 - Eur J Pharmacol. 2011 Feb 10;652(1-3):121-5
20562062 - Eur J Med Res. 2010 May 18;15(5):220-4
22171147 - World J Gastroenterol. 2011 Dec 14;17(46):5117-22
19222098 - World J Gastroenterol. 2009 Feb 14;15(6):727-31
21357821 - Circulation. 2011 Mar 15;123(10):1108-15
20858483 - Eur J Pharmacol. 2010 Dec 15;649(1-3):314-9
20664727 - J Clin Biochem Nutr. 2010 Jul;47(1):27-31
21699808 - Clin Gastroenterol Hepatol. 2011 Sep;9(9):762-768.e6
19794936 - J Clin Biochem Nutr. 2009 Sep;45(2):248-53
19446158 - Clin Ther. 2009 Apr;31(4):849-61
20410834 - J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7
19844108 - Digestion. 2009;80(4):260-6
21245996 - World J Gastroenterol. 2011 Jan 14;17(2):226-30
16948802 - Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908
19192936 - Drugs. 2009;69(1):51-69
7098146 - Jpn J Pharmacol. 1982 Apr;32(2):299-306
21387691 - Nihon Rinsho. 2011 Feb;69(2):369-75
21499703 - J Gastroenterol. 2011 Jun;46(6):724-35
References_xml – reference: 21699808 - Clin Gastroenterol Hepatol. 2011 Sep;9(9):762-768.e6
– reference: 19968611 - Scand J Gastroenterol. 2010 Mar;45(3):292-8
– reference: 21357821 - Circulation. 2011 Mar 15;123(10):1108-15
– reference: 21387691 - Nihon Rinsho. 2011 Feb;69(2):369-75
– reference: 19794936 - J Clin Biochem Nutr. 2009 Sep;45(2):248-53
– reference: 16948802 - Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908
– reference: 20562062 - Eur J Med Res. 2010 May 18;15(5):220-4
– reference: 22093203 - Am Heart J. 2011 Nov;162(5):870-4
– reference: 19844108 - Digestion. 2009;80(4):260-6
– reference: 10792114 - Aliment Pharmacol Ther. 2000 May;14(5):529-34
– reference: 20588029 - Digestion. 2010;82(3):167-72
– reference: 20410834 - J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7
– reference: 21130762 - Eur J Pharmacol. 2011 Feb 10;652(1-3):121-5
– reference: 7098146 - Jpn J Pharmacol. 1982 Apr;32(2):299-306
– reference: 18477341 - Am J Gastroenterol. 2008 May;103(5):1097-103
– reference: 19446158 - Clin Ther. 2009 Apr;31(4):849-61
– reference: 18995219 - Clin Gastroenterol Hepatol. 2008 Nov;6(11):1279-82
– reference: 21464720 - Eur J Gastroenterol Hepatol. 2011 May;23(5):396-404
– reference: 22171147 - World J Gastroenterol. 2011 Dec 14;17(46):5117-22
– reference: 20664727 - J Clin Biochem Nutr. 2010 Jul;47(1):27-31
– reference: 19222098 - World J Gastroenterol. 2009 Feb 14;15(6):727-31
– reference: 21245996 - World J Gastroenterol. 2011 Jan 14;17(2):226-30
– reference: 21072898 - World J Gastroenterol. 2010 Nov 14;16(42):5342-6
– reference: 21499703 - J Gastroenterol. 2011 Jun;46(6):724-35
– reference: 20858483 - Eur J Pharmacol. 2010 Dec 15;649(1-3):314-9
– reference: 19192936 - Drugs. 2009;69(1):51-69
SSID ssj0023352
Score 2.1413302
Snippet AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with...
To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined...
AIM: To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with...
SourceID pubmedcentral
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3167
SubjectTerms Ambulatory Care
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Ulcer Agents - therapeutic use
Aspirin - administration & dosage
Aspirin - adverse effects
Attitude of Health Personnel
Awareness
Brief
Cardiovascular Agents - administration & dosage
Cardiovascular Agents - adverse effects
Chi-Square Distribution
China
Cytoprotection
Drug Prescriptions - statistics & numerical data
Drug Utilization - statistics & numerical data
Gastrointestinal Hemorrhage - chemically induced
Gastrointestinal Hemorrhage - prevention & control
Health Care Surveys
Health Knowledge, Attitudes, Practice
Histamine H2 Antagonists - therapeutic use
Hospitals, University
Humans
L-谷氨酰胺
Practice Patterns, Physicians' - statistics & numerical data
Proton Pump Inhibitors - therapeutic use
Retrospective Studies
联合保护
肠道损伤
胃肠道
药品不良反应
药物
阿司匹林
预防意识
Title Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications
URI http://lib.cqvip.com/qk/84123X/201224/42509230.html
https://www.ncbi.nlm.nih.gov/pubmed/22791953
https://www.proquest.com/docview/1024934385
https://pubmed.ncbi.nlm.nih.gov/PMC3386331
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6F8sILAnGlHDIS-4Aip7H39GOSJqqQQDy0UuiLtbY3RwU2tDGV-EX8TGbWR44WBEjRKt5Lib_x7MzuzGdC3pggE9oy64tBInxuUuUbKYXPEh1lTNpMOnb-9x_kyRl_NxOzTufnVtRSuU766Y9b80r-B1WoA1wxS_YfkG0nhQr4DvhCCQhD-VcYfywwBPIa87lQYWHwcs3IhJmHeIa-yn1wuks85F-Yq_VlgfQQ8FTnjmvjAm5oE3z-BVxki5wBjrcB44ncsfvWhl5twtIJpyNNI0knikaC6jGdaKoZfvBLSIcD16SoFnQi6PCYDqGzpNExtkLNaIqtkykdjWk0dKNGdBS4PpJqhcN1RHUbZgse88LHone-LHvuary0cDkre59AQ-EFxqfm0F6UoA1757ZekusdDQwNkU2GeKWEcfsU7MpqIbauLgTNCp0qaqebmrtsUrFrPYz5_VtrOhhJ4W3rBXLvAMjXF4v-90D3VyHvb0busHCDahuALTy4Q-6GSrmAALcvVLv2mLnmztXrX14diOP0R_uTI4nHssgX3-Be7RpDNzyc_UDdLcvn9AG5X7ss3rCSv4ekY_NHZIWy57Wy5xVzbyN73p7sefuy51Wy56HseY3seRvZ87Zk7zE5m05Oxyd-_doOP-VhuPZlEERzNodSJmA8csZSJlWYJsIIIdQ8S-aZHQirEm4izmUKwxLBlFEZS3Hb8Ak5yIvcPiOekUZZjQzggeGRTk1gLIwwmUrQ95ddctjey_hrRc8SN1B1yVFzc-O0JrzH9658jsHxRWhigCYGaGKAJkZouuRtO6KZ7fd9Xzd4xaCR8ZjN5LYor2BEyCPGmRZd8rTCr50N-Trx4LpL1A6ybQdke99tyVdLx_rOmJaMBYd_-svPyb3NA_WCHKwvS_sSjOZ18srJ6y9UB7ua
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Poor+awareness+of+preventing+aspirin-induced+gastrointestinal+injury+with+combined+protective+medications&rft.jtitle=%E4%B8%96%E7%95%8C%E8%83%83%E8%82%A0%E7%97%85%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Ling-Ling+Zhu+Ling-Cheng+Xu+Yan+Chen+Quan+Zhou+Su+Zeng&rft.date=2012-06-28&rft.issn=1007-9327&rft.eissn=2219-2840&rft.volume=18&rft.issue=24&rft.spage=3167&rft.epage=3172&rft_id=info:doi/10.3748%2Fwjg.v18.i24.3167&rft.externalDocID=42509230
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg